About Bioline  All Journals  Testimonials  Membership  News  Donations

Memórias do Instituto Oswaldo Cruz
Fundação Oswaldo Cruz, Fiocruz
ISSN: 1678-8060
EISSN: 1678-8060
Vol. 109, No. 6, 2014, pp. 828-833
Bioline Code: oc14122
Full paper language: English
Document type: View Point
Document available free of charge

Memórias do Instituto Oswaldo Cruz, Vol. 109, No. 6, 2014, pp. 828-833

 en Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
Zingales, Bianca; Miles, Michael A.; Morases, Carolina B.; Luquestti, Alejandro; Guhl, Felipe; Schijman, Alejandro G. & Ribeiro, Isabela


This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.

in vitro drug screening; T. cruzi genetic diversity; guidelines

© Copyright 2014 - Memórias do Instituto Oswaldo Cruz
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2018, Site last up-dated on 24-Jul-2018.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil